Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00823979 · ClinicalTrials.gov registry record · Phase 2
A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
NCT00823979 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 105 participants.
The verdict
NCT00823979, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
Study Summary
This is a 96 week study to determine if UK- 453,061 in combination with Darunavir /ritonavir and a Nucleos(t)ide Reverse Transcriptase inhibitor is as efficacious, safe and tolerable as etravirine in combination with Darunavir /ritonavir and a Nucleos(t)ide Reverse Transcriptase inhibitor in HIV-1 infected patients who have been previously treated with antiretroviral drugs and have NNRTI resistance mutations.
Interventions
- DRUG Etravirine
- DRUG UK-453,061 Dose 1
- DRUG UK-453,061 Dose 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2009-03-25 |
| Est. Completion | 2012-10-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00823979
The ClinicalTrials.gov registry entry for NCT00823979 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Etravirine is the first listed.
NCT00823979 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00823979 about?
NCT00823979 is a clinical study titled "A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1". This is a 96 week study to determine if UK- 453,061 in combination with Darunavir /ritonavir and a Nucleos(t)ide Reverse Transcriptase inhibitor is as efficacious, safe and tolerable as etravirine in combination with Darunavir /ritonavir and a Nucleos(t)ide Reverse Transcriptase inhibitor in HIV-1 i...
What is the current status of trial NCT00823979?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2009-03-25. Estimated completion is 2012-10-18.
What interventions are being tested in trial NCT00823979?
The interventions under investigation include: Etravirine (DRUG), UK-453,061 Dose 1 (DRUG), UK-453,061 Dose 2 (DRUG).
Who is sponsoring clinical trial NCT00823979?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.